Want to see CUPR full AI Analyst Report?
CUPR Stock Chart & Stats
$0.38
--
Market closed
$0.38
--
Day’s Range― - ―
52-Week Range$1.76 - $76.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.90M
Market Cap
$4.87M
Enterprise Value$15.53M
Total Cash (Recent Filing)$3.12M
Total Debt (Recent Filing)$482.72K
Price to Earnings (P/E)―
Beta0.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding920,625
10 Day Avg. Volume197,362
30 Day Avg. Volume2,899,437
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.08
Price to Sales (P/S)211.01
P/FCF Ratio-1.15
Enterprise Value/Market Cap3.19
Enterprise Value/Revenue579.61
Enterprise Value/Gross Profit-941.13
Enterprise Value/Ebitda-5.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA 510(k) ClearanceU.S. FDA 510(k) clearance creates a durable regulatory beachhead for commercialization in the largest medical market. This credential strengthens clinical credibility, allows direct U.S. market access, and serves as a benchmark to support global rollouts and payer/clinician adoption over the next several quarters.
Nasdaq Listing RestoredRestoring compliance removes immediate listing risk and preserves access to U.S. capital markets and public liquidity. That structural stability improves the company's ability to raise equity or debt non‑urgently, supports investor confidence, and reduces the short‑term financing pressure tied to a delisting threat.
Low Absolute LeverageModest nominal debt reduces near‑term insolvency risk and leaves capacity to fund operations via debt if needed. For a cash‑burning biotech, low leverage is a durable buffer that eases refinancing timing and lowers fixed interest burdens while management pursues commercialization or additional fundraising.
Bears Say
High Cash BurnPersistent negative operating and free cash flow, with a sharp 2025 deterioration, implies structural funding risk. Continued burn will likely force dilutive equity raises or restrictive financing, reducing strategic optionality and making sustained commercialization and R&D investment contingent on external capital.
Deteriorating ProfitabilityA shift to negative gross profit and materially wider losses indicates weakened unit economics or higher cost structure. This structural deterioration limits internal cash generation, undermines path to profitability, and raises questions about scalability of the business model absent cost or commercial improvements.
Entrenched Shareholder ControlDramatic enhancement of Class B voting power and authorization to issue more shares concentrates control and may deter outside investors. Structurally this can limit minority protections, raise governance risk, and influence future capital raises or strategic exits in ways that favor controlling holders.
Cuprina Holdings (Cayman) Limited Class A News
CUPR FAQ
What was Cuprina Holdings (Cayman) Limited Class A’s price range in the past 12 months?
Cuprina Holdings (Cayman) Limited Class A lowest stock price was $1.76 and its highest was $76.00 in the past 12 months.
What is Cuprina Holdings (Cayman) Limited Class A’s market cap?
Cuprina Holdings (Cayman) Limited Class A’s market cap is $4.87M.
When is Cuprina Holdings (Cayman) Limited Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cuprina Holdings (Cayman) Limited Class A’s earnings last quarter?
Currently, no data Available
Is Cuprina Holdings (Cayman) Limited Class A overvalued?
According to Wall Street analysts Cuprina Holdings (Cayman) Limited Class A’s price is currently Overvalued.
Does Cuprina Holdings (Cayman) Limited Class A pay dividends?
Cuprina Holdings (Cayman) Limited Class A does not currently pay dividends.
What is Cuprina Holdings (Cayman) Limited Class A’s EPS estimate?
Cuprina Holdings (Cayman) Limited Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cuprina Holdings (Cayman) Limited Class A have?
Cuprina Holdings (Cayman) Limited Class A has 920,625 shares outstanding.
What happened to Cuprina Holdings (Cayman) Limited Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cuprina Holdings (Cayman) Limited Class A?
Currently, no hedge funds are holding shares in CUPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Technical Analysis
GeoVax Labs
―
HCW Biologics
―
Calidi Biotherapeutics
―
Psyence Biomedical
―
Aspire Biopharma Holdings
―
Ownership Overview
―
Insiders
0.17% Mutual Funds
― Other Institutional Investors
99.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---